PPM1D Is a Therapeutic Target in Childhood Neural Tumors

Childhood medulloblastoma and high-risk neuroblastoma frequently present with segmental gain of chromosome 17q corresponding to aggressive tumors and poor patient prognosis. Located within the 17q-gained chromosomal segments is PPM1D at chromosome 17q23.2. PPM1D encodes a serine/threonine phosphatas...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-11, Vol.13 (23), p.6042
Main Authors: Milosevic, Jelena, Treis, Diana, Fransson, Susanne, Gallo-Oller, Gabriel, Sveinbjörnsson, Baldur, Eissler, Nina, Tanino, Keiji, Sakaguchi, Kazuyasu, Martinsson, Tommy, Wickström, Malin, Kogner, Per, Johnsen, John Inge
Format: Article
Language:English
Subjects:
Apoptosis
Breast cancer
Cancer and Oncology
Cancer och onkologi
Cell cycle
Cell division
Cell growth
Cell survival
Central nervous system
Children
Chromosome 17
Chromosomes
CRISPR
Deoxyribonucleic acid
DNA
DNA damage
DNA repair
Gene amplification
Genetic engineering
MDM2 protein
Medicin och hälsovetenskap
Medulloblastoma
Mutation
Neuroblastoma
Neuroblasts
p53 Protein
Phosphatase
Phosphorylation
Prognosis
Protein-serine/threonine phosphatase
Regulation
Therapeutic targets
Threonine phosphatase
Tumorigenesis
Tumors
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Childhood medulloblastoma and high-risk neuroblastoma frequently present with segmental gain of chromosome 17q corresponding to aggressive tumors and poor patient prognosis. Located within the 17q-gained chromosomal segments is PPM1D at chromosome 17q23.2. PPM1D encodes a serine/threonine phosphatase, WIP1, that is a negative regulator of p53 activity as well as key proteins involved in cell cycle control, DNA repair and apoptosis. Here, we show that the level of PPM1D expression correlates with chromosome 17q gain in medulloblastoma and neuroblastoma cells, and both medulloblastoma and neuroblastoma cells are highly dependent on PPM1D expression for survival. Comparison of different inhibitors of WIP1 showed that SL-176 was the most potent compound inhibiting medulloblastoma and neuroblastoma growth and had similar or more potent effects on cell survival than the MDM2 inhibitor Nutlin-3 or the p53 activator RITA. SL-176 monotherapy significantly suppressed the growth of established medulloblastoma and neuroblastoma xenografts in nude mice. These results suggest that the development of clinically applicable compounds inhibiting the activity of WIP1 is of importance since PPM1D activating mutations, genetic gain or amplifications and/or overexpression of WIP1 are frequently detected in several different cancers.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13236042